LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...

Check the time stamp on this data. Updated AI-Generated Signals for Keros Therapeutics Inc. (KROS) available here: KROS. Type a few symbols and Take a Trial. The signals for these will appear ...

NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, announced it will present during the plenary session of the 13th AA ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?

Minister for Planning Ahsan Iqbal chaired a meeting of the Central Development Working Party (CDWP) which approved 16 development projects worth Rs.

The law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). The investigation concerns whether Keros and/or certain ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

Keros Therapeutics (KROS) stock rises as a licensing deal with Takeda (TAK) begins. However, Cantor Fitzgerald downgrades, citing a trial setback. Read more here.